Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Cytochrome P-450 Enzyme Inhibitors
Prostatic Neoplasms, Castration-Resistant
The updated results of this ongoing study showed that disease progression was delayed in patients with advanced prostate cancer who were treated with abiraterone acetate and prednisone, and there was a continued trend in prolongation of life compared with patients treated with prednisone alone. Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr.